🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Multiple Myeloma in Relapse

A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 NCT07623798Phase 31 site📍 Shanghai Innovent Biologics (Suzhou) Co. Ltd. · Tests: Pomalidomide Capsules, Bortezomib for Injection, Daratumumab Injection (Subcutaneous Injection), IBI3003, Selinexor Tab… Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07359014NA1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Dual CD19/BCMA CAR-T Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma NCT07096778Phase 231 sites📍 Phoenix📍 San Francisco📍 Jacksonville CellCentric Ltd. · Tests: Inobrodib, Pomalidomide, Dexamethasone A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) NCT05519085Phase 3266 sites📍 Los Alamitos📍 San Diego📍 West Hollywood Celgene · Tests: mezigdomide, Pomalidomide, Bortezomib, Dexamethasone Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma NCT05530421Phase 23 sites📍 Coral Gables📍 Deerfield Beach📍 Miami University of Miami · Tests: Selinexor, Venetoclax, Dexamethasone A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies NCT05908409Phase 1, Phase 211 sites📍 Santander📍 Salamanca📍 Barcelona IDP Discovery Pharma S.L. · Tests: IDP-121 A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM) NCT07227311Phase 259 sites📍 Los Alamitos📍 Torrance📍 Whittier GlaxoSmithKline · Tests: Belantamab mafodotin, Dexamethasone, Pomalidomide, Bortezomib, Carfilzomib A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma NCT04973605Phase 1, Phase 274 sites📍 Birmingham📍 Duarte📍 Irvine BeOne Medicines · Tests: Sonrotoclax, Dexamethasone, Carfilzomib, Daratumumab, Pomalidomide An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies NCT07101705EARLY Phase 11 site📍 Wuhan Union Hospital, Tongji Medical College, Huazhong University… · Tests: OriV508 Injection A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site📍 Camden Roger Strair · Tests: Soursop tea A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD" NCT07382739Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Elranatamab Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies NCT05887167Phase 11 site📍 Los Angeles Joshua Sasine, MD, PhD · Tests: autologous hematopoietic stem cells added to planned CAR T Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma NCT07657312Phase 21 site📍 Columbus Naresh Bumma · Tests: Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) NCT06759181Phase 1, Phase 21 site📍 Xuzhou Xuzhou Medical University · Tests: anti-BCMA/FcRL5 CAR T Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma NCT06245629n/a1 site📍 Uppsala Uppsala University · Tests: Bortezomib-bendamustine-melphalan A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients NCT06508983Phase 312 sites📍 Beijing📍 Guangzhou📍 Guangzhou Hangzhou Sumgen Biotech Co., Ltd. · Tests: SG301 Injection, SG301 placebo, pomalidomide, dexamethasone Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager NCT07094048Phase 42 sites📍 Lévis📍 Québec CHU de Quebec-Universite Laval · Tests: Target trough IgG level of 8-10 g/L, Target trough IgG level 4-6 g/L, No history of recurrent or severe infections and … Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients NCT07210047Phase 1, Phase 21 site📍 Taipei HuniLife Biotechnology, Inc. · Tests: HuL001, Lenalidomide/Dexamethasone BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease NCT04271644Phase 1, Phase 21 site📍 Kunming Chongqing Precision Biotech Co., Ltd · Tests: BCMA CAR-T cells Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis NCT06971380Phase 21 site📍 Jerusalem Polina Stepensky · Tests: HBI0101 CART A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma NCT06630806Phase 119 sites📍 Phoenix📍 Jacksonville📍 Rochester Sanofi · Tests: SAR446523 A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma NCT07681596Phase 1, Phase 212 sites📍 Duarte📍 Denver📍 Tampa AstraZeneca · Tests: AZD4045, Daratumumab, Aldesleukin Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM) NCT06196255Phase 1, Phase 21 site📍 Xuzhou Xuzhou Medical University · Tests: anti-FcRL5 CAR-T Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma NCT04879043Phase 1, Phase 224 sites📍 Atlanta📍 Louisville📍 Omaha Heidelberg Pharma AG · Tests: HDP-101 A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) NCT05927571Phase 114 sites📍 Camperdown📍 Waratah📍 Adelaide Genentech, Inc. · Tests: Cevostamab, Elranatamab, Tocilizumab Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease NCT06793475NA2 sites📍 Beijing📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: anti-BCMA/GPRC5D bispecific CAR-T, Apornemin, Carfilzomib, Thalidomide, Dexamethasone Efficacy of Isatuximab-based Regimens in Relapsed/Refractory Multiple Myeloma With 1q21+ NCT06874530n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma NCT06158412Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: All-trans Retinoic Acid in combination with the KPD Regimen Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma NCT07497165n/a1 site📍 Taiyuan Shanxi Bethune Hospital A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma NCT07579234Phase 31 site📍 Tianjing Shandong New Time Pharmaceutical Co., LTD · Tests: F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy